Tectonic completes enrollment of 191 patients in TX45 Phase 2 PH-HFpEF trial
Tectonic Therapeutic completed enrollment in its APEX Phase 2 clinical trial testing TX45 in pulmonary hypertension patients, with 72% of participants in the targeted severe disease subtype. Topline results are expected in early Q1 2027, a key catalyst for the clinical-stage biot
View filing at SEC.gov →